Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alvogen Inc.

www.alvogen.com

Latest From Alvogen Inc.

Alvotech And JAMP Partner On Canadian Biosimilars

Alvotech and JAMP Pharma have struck a partnership deal to market five biosimilars in Canada that have a combined current branded market value of more than $2bn annually.

Deals Biosimilars

Deal Watch: Pfizer, Biogen Partnership One Of Many As JPM Gets Underway

Although there was no major acquisition starting out the J.P. Morgan Healthcare Conference, the deal-making flow has been steady. Pfizer licensed a neurodegenerative disease candidate to Biogen, while also selling Axsome rights to reboxetine in narcolepsy and fibromyalgia. Biogen signed a neurology R&D collaboration with CAMP4 as well.

Deals M & A

Alvogen Licenses Mithra Contraceptive In Asia

Alvogen is expanding its presence in Asia by licensing a novel oral contraceptive from Belgium’s Mithra and striking a deal to market Orion’s Parkinson’s disease drugs.

Deals Gynecology & Urology

Scrip Asks…What Does 2020 Hold For Biopharma? Part 3: Policy And Regulation

The US election will intensify  the spotlight on drug costs, regulators will have their hands full with advanced therapy filings, and the need to address rising infectious disease threats will mount. Biosimilars, cannabis and Brexit are among other hot topics for 2020.

Policy Regulation
See All

Company Information

  • Industry
  • Contract Research, Toxicology Testing-CRO
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Topical Delivery
      • Transdermal
    • Generic Drugs
    • Nutraceuticals
    • OTC, Consumer
  • Services
  • Therapeutic Areas
  • Cancer
  • Cardiovascular
  • Gastrointestinal
  • Neurology, Nervous System
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Alvogen Inc.
  • Senior Management
  • Robert Wessman, Chmn. & CEO
    Joel Morales, CFO
    Thor Kristjansson, EVP, M&As
    Faysal Kalmoua, EVP, Portfolio
    Martina Feitzinger, EVP, Strategic Regulatory Affairs
  • Contact Info
  • Alvogen Inc.
    Phone: (973) 796-3400
    44 Whippany Rd.
    Ste. 300
    Morristown, NJ 07960
    USA
UsernamePublicRestriction

Register